심근 트로포닌 시장 : 시장 규모, 점유율 , 성장률, 산업 분석, 유형별, 용도별, 지역별 고찰 및 예측(2026-2034년)

Growth Factors of cardiac troponin Market

The global cardiac troponin market is witnessing robust growth, driven by the rising prevalence of cardiovascular diseases, growing adoption of advanced diagnostic technologies, and increasing emphasis on early detection of myocardial injury. Cardiac troponin is a highly specific biomarker used for the diagnosis of myocardial infarction (MI) and acute coronary syndromes (ACS). Its ability to detect even minimal cardiac muscle damage has made it an indispensable tool in emergency and critical care settings.

In 2025, the global cardiac troponin market was valued at USD 3.50 billion. The market is projected to grow to USD 3.78 billion in 2026 and further expand to USD 7.17 billion by 2034, registering a CAGR of 8.30% from 2026 to 2034. This steady expansion reflects the increasing burden of heart-related disorders worldwide and the continuous evolution of high-sensitivity testing solutions.

Market Drivers

The growing prevalence of cardiovascular diseases (CVDs) remains the primary driver of the cardiac troponin market. According to the Centers for Disease Control and Prevention (CDC), in the U.S., one person experiences a heart attack every 40 seconds, highlighting the urgent need for rapid and accurate diagnostic tools. Elevated troponin levels are directly linked to myocardial injury, making troponin testing a standard protocol for diagnosing heart attacks and monitoring disease progression.

Additionally, the aging global population is significantly contributing to market growth. Older adults are more susceptible to chronic conditions such as hypertension, coronary artery disease, and heart failure. The increasing geriatric population is driving higher hospitalization rates and demand for cardiac biomarker testing, including troponin assays.

Market Trends

A key trend shaping the market is the increasing adoption of high-sensitivity and point-of-care (POC) troponin tests. These advanced tests enable faster turnaround times and improved diagnostic accuracy, particularly in emergency departments. High-sensitivity assays can detect very low levels of troponin, allowing early identification of myocardial infarction and differentiation between acute and chronic cardiac conditions.

Technological advancements and regulatory approvals are further accelerating adoption. For instance, the U.S. FDA's approval of high-sensitivity troponin assays has strengthened their clinical acceptance and expanded their use in routine cardiac diagnostics.

Restraining Factors

Despite strong growth prospects, the market faces challenges related to the limited sensitivity of conventional troponin assays. Traditional tests may fail to detect low troponin concentrations during the early hours following myocardial injury, potentially delaying diagnosis. This limitation underscores the need for advanced high-sensitivity assays but also restricts adoption in regions with limited access to newer technologies.

Segmentation Analysis

By type, the market is segmented into troponin I and troponin T. The troponin I segment dominated the market in 2026, accounting for 73.32% of the global share, due to its high cardiac specificity and widespread use in MI diagnosis. The troponin T segment is expected to witness steady growth, supported by increasing regulatory approvals and its expanding role in heart failure screening.

Based on setting, the market is divided into laboratory testing and point-of-care testing. Laboratory testing held the largest share in 2026 at 73.68%, driven by higher accuracy and detailed quantitative analysis. However, the POC testing segment is expected to grow at a faster rate due to increasing use in emergency and resource-limited settings.

By end user, hospitals and clinics dominated the market with a 63.44% share in 2026, owing to high patient admissions and extensive use of troponin tests in emergency cardiac care.

Regional Insights

North America dominated the global cardiac troponin market in 2025, accounting for 41.15% share and generating USD 1.44 billion in revenue. The region benefits from advanced healthcare infrastructure, favorable reimbursement policies, and high adoption of high-sensitivity assays. The U.S. market is projected to reach USD 1.40 billion by 2026.

Europe held the second-largest share, supported by widespread adoption of CE-marked high-sensitivity assays and strong regulatory frameworks. Asia Pacific is anticipated to be the fastest-growing region due to rising cardiovascular disease prevalence, expanding diagnostic infrastructure, and increasing awareness. By 2026, China, Japan, and India are projected to reach USD 0.28 billion, USD 0.19 billion, and USD 0.14 billion, respectively.

Competitive Landscape

The cardiac troponin market is moderately competitive, with key players focusing on product innovation, regulatory approvals, and strategic collaborations. F. Hoffmann-La Roche Ltd. leads the market due to its strong high-sensitivity troponin portfolio. Other prominent players include Abbott, Siemens Healthineers, bioMerieux, Beckman Coulter, and QuidelOrtho.

Conclusion

The global cardiac troponin market is poised for strong and sustained growth over the forecast period, driven by the rising burden of cardiovascular diseases, expanding geriatric population, and rapid adoption of high-sensitivity and point-of-care diagnostic technologies. From a market size of USD 3.50 billion in 2025, the industry is expected to reach USD 7.17 billion by 2034. While limitations of conventional assays remain a challenge, continuous technological advancements, increasing regulatory approvals, and growing emphasis on early cardiac diagnosis are expected to unlock significant growth opportunities. Overall, cardiac troponin testing will remain a cornerstone of modern cardiovascular diagnostics worldwide.

Segmentation

By Type

• Troponin T
• Troponin I

By Setting

• Laboratory Testing
• Point-of-Care (POC) Testing

By Indication

• Myocardial Infarction
• Congestive Heart Failure
• Acute Coronary Syndrome
• Others

By End User

• Hospitals & Clinics
• Diagnostic Laboratories
• Homecare Settings & Others

By Region

• North America ( By Type, By Setting, By Indication, By End User, By Country)
  • U.S.
  • Canada
• Europe ( By Type, By Setting, By Indication, By End User, By Country/Sub-Region)
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific ( By Type, By Setting, By Indication, By End User, By Country/Sub-Region)
  • China
  • Japan
  • India
  • Australia
  • Rest of Asia Pacific
• Latin America ( By Type, By Setting, By Indication, By End User, By Country/Sub-Region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Type, By Setting, By Indication, By End User, By Country/Sub-Region)
  • GCC
  • South Africa
• Rest of Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Prevalence of Key Cardiovascular Diseases, By Key Countries/Regions, 2024/2025
• 4.2. Technological Advancements in Cardiac Troponin Testing
• 4.3. New Product Launches. By Key Players
• 4.4. Key Industry Developments (Mergers, Acquisitions, Partnerships etc.)
• 4.5. Impact of COVID-19 on the Market

5. Global Cardiac Troponin Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Type
  • 5.1.1. Troponin T
  • 5.1.2. Troponin I
• 5.2. Market Analysis, Insights and Forecast - By Setting
  • 5.2.1. Laboratory Testing
  • 5.2.2. Point-of-Care (POC) Testing
• 5.3. Market Analysis, Insights and Forecast - By Indication
  • 5.3.1. Myocardial Infarction
  • 5.3.2. Congestive Heart Failure
  • 5.3.3. Acute Coronary Syndrome
  • 5.3.4. Others
• 5.4. Market Analysis, Insights and Forecast - By End-User
  • 5.4.1. Hospitals & Clinics
  • 5.4.2. Diagnostic Laboratories
  • 5.4.3. Homecare Settings & Others
• 5.5. Market Analysis, Insights and Forecast - By Region
  • 5.5.1. North America
  • 5.5.2. Europe
  • 5.5.3. Asia Pacific
  • 5.5.4. Latin America
  • 5.5.5. Middle East & Africa

6. North America Cardiac Troponin Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Type
  • 6.1.1. Troponin T
  • 6.1.2. Troponin I
• 6.2. Market Analysis, Insights and Forecast - By Setting
  • 6.2.1. Laboratory Testing
  • 6.2.2. Point-of-Care (POC) Testing
• 6.3. Market Analysis, Insights and Forecast - By Indication
  • 6.3.1. Myocardial Infarction
  • 6.3.2. Congestive Heart Failure
  • 6.3.3. Acute Coronary Syndrome
  • 6.3.4. Others
• 6.4. Market Analysis, Insights and Forecast - By End-User
  • 6.4.1. Hospitals & Clinics
  • 6.4.2. Diagnostic Laboratories
  • 6.4.3. Homecare Settings & Others
• 6.5. Market Analysis, Insights and Forecast - By Country
  • 6.5.1. U.S.
  • 6.5.2. Canada

7. Europe Cardiac Troponin Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Type
  • 7.1.1. Troponin T
  • 7.1.2. Troponin I
• 7.2. Market Analysis, Insights and Forecast - By Setting
  • 7.2.1. Laboratory Testing
  • 7.2.2. Point-of-Care (POC) Testing
• 7.3. Market Analysis, Insights and Forecast - By Indication
  • 7.3.1. Myocardial Infarction
  • 7.3.2. Congestive Heart Failure
  • 7.3.3. Acute Coronary Syndrome
  • 7.3.4. Others
• 7.4. Market Analysis, Insights and Forecast - By End-User
  • 7.4.1. Hospitals & Clinics
  • 7.4.2. Diagnostic Laboratories
  • 7.4.3. Homecare Settings & Others
• 7.5. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 7.5.1. U.K.
  • 7.5.2. Germany
  • 7.5.3. France
  • 7.5.4. Italy
  • 7.5.5. Spain
  • 7.5.6. Rest of Europe

8. Asia Pacific Cardiac Troponin Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Type
  • 8.1.1. Troponin T
  • 8.1.2. Troponin I
• 8.2. Market Analysis, Insights and Forecast - By Setting
  • 8.2.1. Laboratory Testing
  • 8.2.2. Point-of-Care (POC) Testing
• 8.3. Market Analysis, Insights and Forecast - By Indication
  • 8.3.1. Myocardial Infarction
  • 8.3.2. Congestive Heart Failure
  • 8.3.3. Acute Coronary Syndrome
  • 8.3.4. Others
• 8.4. Market Analysis, Insights and Forecast - By End-User
  • 8.4.1. Hospitals & Clinics
  • 8.4.2. Diagnostic Laboratories
  • 8.4.3. Homecare Settings & Others
• 8.5. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 8.5.1. China
  • 8.5.2. India
  • 8.5.3. Japan
  • 8.5.4. Australia
  • 8.5.5. Rest of Asia Pacific

9. Latin America Cardiac Troponin Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Type
  • 9.1.1. Troponin T
  • 9.1.2. Troponin I
• 9.2. Market Analysis, Insights and Forecast - By Setting
  • 9.2.1. Laboratory Testing
  • 9.2.2. Point-of-Care (POC) Testing
• 9.3. Market Analysis, Insights and Forecast - By Indication
  • 9.3.1. Myocardial Infarction
  • 9.3.2. Congestive Heart Failure
  • 9.3.3. Acute Coronary Syndrome
  • 9.3.4. Others
• 9.4. Market Analysis, Insights and Forecast - By End-User
  • 9.4.1. Hospitals & Clinics
  • 9.4.2. Diagnostic Laboratories
  • 9.4.3. Homecare Settings & Others
• 9.5. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 9.5.1. Brazil
  • 9.5.2. Mexico
  • 9.5.3. Rest of Latin America

10. Middle East & Africa Cardiac Troponin Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Type
  • 10.1.1. Troponin T
  • 10.1.2. Troponin I
• 10.2. Market Analysis, Insights and Forecast - By Setting
  • 10.2.1. Laboratory Testing
  • 10.2.2. Point-of-Care (POC) Testing
• 10.3. Market Analysis, Insights and Forecast - By Indication
  • 10.3.1. Myocardial Infarction
  • 10.3.2. Congestive Heart Failure
  • 10.3.3. Acute Coronary Syndrome
  • 10.3.4. Others
• 10.4. Market Analysis, Insights and Forecast - By End-User
  • 10.4.1. Hospitals & Clinics
  • 10.4.2. Diagnostic Laboratories
  • 10.4.3. Homecare Settings & Others
• 10.5. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 10.5.1. GCC
  • 10.5.2. South Africa
  • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. F. Hoffmann-La Roche Ltd.
    • 11.2.1.1. Overview
    • 11.2.1.2. Products
    • 11.2.1.3. SWOT Analysis
    • 11.2.1.4. Recent Developments
    • 11.2.1.5. Strategies
    • 11.2.1.6. financials (Based on Availability)
  • 11.2.2. bioMerieux SA
    • 11.2.2.1. Overview
    • 11.2.2.2. Products
    • 11.2.2.3. SWOT Analysis
    • 11.2.2.4. Recent Developments
    • 11.2.2.5. Strategies
    • 11.2.2.6. financials (Based on Availability)
  • 11.2.3. Abbott
    • 11.2.3.1. Overview
    • 11.2.3.2. Products
    • 11.2.3.3. SWOT Analysis
    • 11.2.3.4. Recent Developments
    • 11.2.3.5. Strategies
    • 11.2.3.6. financials (Based on Availability)
  • 11.2.4. Siemens Healthineers AG
    • 11.2.4.1. Overview
    • 11.2.4.2. Products
    • 11.2.4.3. SWOT Analysis
    • 11.2.4.4. Recent Developments
    • 11.2.4.5. Strategies
    • 11.2.4.6. financials (Based on Availability)
  • 11.2.5. Eurolyser Diagnostica GmbH
    • 11.2.5.1. Overview
    • 11.2.5.2. Products
    • 11.2.5.3. SWOT Analysis
    • 11.2.5.4. Recent Developments
    • 11.2.5.5. Strategies
    • 11.2.5.6. financials (Based on Availability)
  • 11.2.6. QuidelOrtho (Quidel Corporation)
    • 11.2.6.1. Overview
    • 11.2.6.2. Products
    • 11.2.6.3. SWOT Analysis
    • 11.2.6.4. Recent Developments
    • 11.2.6.5. Strategies
    • 11.2.6.6. financials (Based on Availability)
  • 11.2.7. PerkinElmer Inc.
    • 11.2.7.1. Overview
    • 11.2.7.2. Products
    • 11.2.7.3. SWOT Analysis
    • 11.2.7.4. Recent Developments
    • 11.2.7.5. Strategies
    • 11.2.7.6. financials (Based on Availability)
  • 11.2.8. Beckman Coulter, Inc. (Danaher)
    • 11.2.8.1. Overview
    • 11.2.8.2. Products
    • 11.2.8.3. SWOT Analysis
    • 11.2.8.4. Recent Developments
    • 11.2.8.5. Strategies
    • 11.2.8.6. financials (Based on Availability)
  • 11.2.9. RESPONSE BIOMEDICAL
    • 11.2.9.1. Overview
    • 11.2.9.2. Products
    • 11.2.9.3. SWOT Analysis
    • 11.2.9.4. Recent Developments
    • 11.2.9.5. Strategies
    • 11.2.9.6. financials (Based on Availability)
  • 11.2.10. LifeSign LLC.
    • 11.2.10.1. Overview
    • 11.2.10.2. Products
    • 11.2.10.3. SWOT Analysis
    • 11.2.10.4. Recent Developments
    • 11.2.10.5. Strategies
    • 11.2.10.6. financials (Based on Availability)